Overview

NAC Effect on Infertile Women With Endometrioma

Status:
Recruiting
Trial end date:
2023-11-30
Target enrollment:
0
Participant gender:
Female
Summary
Oxidative stress has been investigated as a key factor in the pathogenesis and progression of endometrioma. High follicular fluid ROS levels and serum can be related to negative IVF/ICSI outcomes in infertile women with endometrioma. Therefore, the use of antioxidants such as N-acetyl cysteine (NAC) may be reduced complications of endometrioma. To study this hypothesis, we designed a double-blind, randomized clinical trial study that aimed to determine the effect of N-acetyl cysteine (NAC) on stress oxidative factors and pregnancy outcomes in IVF/ICSI cycles in endometrioma patients.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Royan Institute
Treatments:
Acetylcysteine
N-monoacetylcystine
Criteria
Inclusion Criteria:

- Age between 20 and 42 years

- Ultrasound or laparoscopic diagnosis of moderate to sever endometrioma (endometriosis
stage III and IV)

- Serum AMH levels between 0.7 and 4.5 ng/ml

- Standard long GnRH and antagonist ovulation stimulation cycle

- Body mass index (BMI) <30 kg/m2

Exclusion Criteria:

- Non-inclusion criteria: Congenital uterine malformations

- Severe male infertility (TESE, PESA)

- Past medical history of asthma